|
181 Independent
prescribers may be ready for 2007 following Council's approval of training
curriculum Pharmacists could qualify as independent prescribers
by the end of the year, following endorsement of a curriculum for the
education and training of independent prescribers by the Council of the
Royal Pharmaceutical Society
PJ 2006;277:181
Full Text
181 MHRA issues
warning over potencies of beclometasone inhalers The two CFC-free beclometasone dipropionate inhalers on the UK market — Clenil Modulite and Qvar — are not equipotent and this needs to be taken into account when the products are prescribed and dispensed, the Medicines and Healthcare products Regulatory Agency warned this week
PJ 2006;277:181
Full Text
181 Consultation launched
on pension changes NHS staff and employers in England and Wales are
being asked to comment on planned changes to the NHS pension scheme
PJ 2006;277:181
Full Text
182 AIDS
progression remains a problem despite HAART Virological response after starting highly active antiretroviral therapy (HAART) has improved with each year of its use, according to an analysis of a decade's experience with HAART in Europe and North America, published in The
Lancet ahead of this month's International AIDS Conference in Toronto
PJ 2006;277:182
Full Text
182 Systematic strategy
outlined for heavily treated HIV-infected patients A strategy for
dealing with heavily treated HIV-infected patients who are experiencing treatment
failure with multiple classes of antiretrovirals is proposed in the latest issue
of Lancet Infectious Diseases
PJ 2006;277:182
Full Text
182 Latest study offers
new hope for HIV treatment interruption Patients with HIV undergoing
CD4-guided treatment interruption saw substantial drug savings and no evidence
of increased treatment resistance compared with those on continuous highly active
antiretroviral therapy, researchers claim
PJ 2006;277:182
Full Text
182 Aptivus risks highlighted The risks of intracranial haemorrhage in patients receiving Aptivus (tipranavir) have been highlighted in a letter sent to health professionals by Boehringer Ingelheim, the drug's manufacturer, last week
PJ 2006;277:182
Full Text
183 Details
of revised zero discount arrangements published Details of the products
that are expected to be removed from zero discount arrangements have been published
PJ 2006;277:183
Full Text
183 Locum pharmacists
find voice on the internet Locum pharmacists can share their views
via a new internet forum
PJ 2006;277:183
Full Text
183 Staff training in
Scotland Pharmacy contractors in Scotland will be able to claim £750 towards the cost of training pharmacy staff during this financial year
PJ 2006;277:183
Full Text
183 Two new cancer drugs
launched this week Two new oncology medicines have been launched this
week. Bioenvision has launched clofarabine (Evoltra) for the treatment of children
with acute lymphoblastic leukaemia and Bayer has launched sorafenib (Nexavar),
a protein kinase inhibitor for renal cell carcinoma
PJ 2006;277:183
Full Text
183 Plan to simplify OTC
warnings A code of practice for the design of over-the-counter medicines
packs is being developed through the Better Regulation of Over the Counter Medicines
Initiative, health minister Lord Warner announced earlier this week
PJ 2006;277:183
Full Text
183 Optometrist prescribing
plans Consultation on enabling optometrists to become independent
prescribers has been launched by the Medicines and Healthcare products Regulatory
Agency and the Department of Health
PJ 2006;277:183
Full Text
183 AMD risk factors Regular
consumption of fish is associated with a lower risk of developing age-related
macular degeneration, whereas smoking appears to double the risk, and hormone
replacement therapy has no effect on the chances of developing this eye condition,
data from studies published in reveal
PJ 2006;277:183
Full Text
184 Macular
degeneration treatment among drugs accepted by SMC Pegaptanib (Macugen)
intravitreal injection, a new medicine for the treatment of neovascular (wet)
age-related macular degeneration, has been accepted by the Scottish Medicines
Consortium for use throughout NHS Scotland. The SMC is restricting pegaptanib
use based on patients' visual acuity, and a guideline on when treatment should
be stopped is provided by the consortium
PJ 2006;277:184
Full Text
184 Changes to supply
of home oxygen service revealed Negotiations to change suppliers
of the home oxygen service are under way in some parts of England and Wales,
it was revealed this week
PJ 2006;277:184
Full Text
184 Minocycline not first-line
tetracycline for acne Minocycline should not be used in preference
to other tetracyclines for the treatment of acne, the Drug and Therapeutics
Bulletinhas suggested in its latest review
PJ 2006;277:184
Full Text
|
The
Pharmaceutical Journal